Status:
RECRUITING
The MELAcare Study: A New Method for Surveillance of Melanoma Patients
Lead Sponsor:
Herlev and Gentofte Hospital
Collaborating Sponsors:
Danish Cancer Society
Conditions:
Cutaneous Melanoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The aim of this study is to evaluate a new method of follow-up for patients with low and intermediate risk (stages IA-IIA) melanoma. The investigators will compare different tools for patient support ...
Eligibility Criteria
Inclusion
- Ability to read and understand Danish language
- Willing and able to give written informed consent
- Surgical treatment of a clinical stage IA-IIA melanoma within 3 months of inclusion
Exclusion
- Advanced melanoma, clinical stages IIB, IIC, III, or IV
- Patients with high risk of a new primary melanoma (dysplastic nevus syndrome, or family history of melanoma)
- History of melanoma skin cancer prior to the index diagnosis
- Previous cancer, excluding non-melanoma skin cancer
- Comorbidity that makes skin self-examination impossible (e.g. physical or mental disabilities, dementia or decreased cognitive function)
- non-detection of sentinel node in IB and IIA patients
Key Trial Info
Start Date :
March 9 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2028
Estimated Enrollment :
378 Patients enrolled
Trial Details
Trial ID
NCT05253872
Start Date
March 9 2022
End Date
March 1 2028
Last Update
June 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Herlev and Gentofte Hospital
Copenhagen, Denmark, 2730